Hydrogen‐bond mediated coupling of 1,2,3‐triazoles to indoles and pyrroles results in N2 selective functionalization of the triazole moiety in moderate to excellent yields. The reaction was tolerant of un‐, mono‐ and disubstituted triazoles and was applied to synthesize tryptophan derived fluorescent amino acids.
Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinophathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
On Water Cu@g‐C
<sub>3</sub>
N
<sub>4</sub>
Catalyzed Synthesis of NH‐1,2,3‐Triazoles via [2+3] Cycloadditions of Nitroolefins/Alkynes and Sodium Azide
作者:Soumen Payra、Arijit Saha、Subhash Banerjee
DOI:10.1002/cctc.201801524
日期:2018.12.7
CuCl2 (Cu@g‐C3N4) and characterized by powder X‐ray diffraction, field emission scanning electron microscopy, high resolution transmission electron microscopy, X‐ray photoelectron spectroscopy studies. An efficient and regioselective protocol for the on watersynthesis of 4‐aryl‐NH‐1,2,3‐triazole derivatives via 1,3‐diipolar cycloaddition reactions of nitroolefins/phenylacetylenes to sodiumazide were
在这里,我们报道了石墨聚合的C 3 N 4负载的CuCl 2(Cu @ g‐C 3 N 4)的制造,其特征在于粉末X射线衍射,场发射扫描电子显微镜,高分辨率透射电子显微镜,X射线光电子能谱研究。通过使用Cu @ g-C 3证明了通过硝基烯烃/苯基乙炔与叠氮化钠的1,3-二极性环加成反应进行水合成4-芳基-NH -1,2,3-三唑衍生物的高效且区域选择性的方案N 4作为坚固且可重复使用的催化剂。
METALLOENZYME INHIBITOR COMPOUNDS
申请人:Innocrin Pharmaceuticals, Inc.
公开号:US20170143694A1
公开(公告)日:2017-05-25
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
本发明描述了具有金属酶调节活性的化合物,以及治疗由这些金属酶介导的疾病、疾病或症状的方法。
Triazole inhibitors of type 2 methionine aminopeptidase
申请人:Kallander S. Lara
公开号:US20050004116A1
公开(公告)日:2005-01-06
Disclosed are compounds which are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.